Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research  How it helps Latest publication
CC12.1
Potential treatment - pre-clinical evidence Experimental Antiviral
Regdanvimab
Authorized Experimental Antiviral
Convalescent plasma
Emergency use authorization Experimental Antiviral May/16/2022
mAb 222
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb Beta-55
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
COVA1-16
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/08/2021
mAb Beta-29
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
MVC-COV1901
Potential treatment - pre-clinical evidence Experimental Vaccine Nov/29/2020
S96
Potential treatment - pre-clinical evidence Experimental Antiviral
PCI-27483
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/12/2021
mAb Beta-22
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/27/2021
BRII-198
Potential treatment - theoretical effect Experimental Antiviral Dec/23/2021
NSC Ex/Mv
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/18/2020
BNT162b1
Potential treatment - clinical evidence Experimental Vaccine Aug/12/2020
Y-320
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
BRII-196
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/23/2021
Full-length Spike protein
Potential treatment - pre-clinical evidence Experimental Vaccine Mar/29/2021
STE73-2E9
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/11/2021
Emetine
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/10/2021
NVX-CoV2373
Potential treatment - clinical evidence Experimental Vaccine Apr/07/2021